Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility.

IF 3.1 Q2 ONCOLOGY Oncology Reviews Pub Date : 2019-02-04 eCollection Date: 2019-01-14 DOI:10.4081/oncol.2019.389

Mohammad Shahjahani, Elham Homaei Hadad, Shirin Azizidoost, Kowsar Chenani Nezhad, Saeid Shahrabi

{"title":"Complex karyotype in myelodysplastic syndromes: Diagnostic procedure and prognostic susceptibility.","authors":"Mohammad Shahjahani, Elham Homaei Hadad, Shirin Azizidoost, Kowsar Chenani Nezhad, Saeid Shahrabi","doi":"10.4081/oncol.2019.389","DOIUrl":null,"url":null,"abstract":"Complex karyotype (CK) is a poor prognosis factor in hematological malignancies. Studies have shown that the presence of CK in myelodysplastic syndrome (MDS) can be associated with MDS progression to acute myeloid leukemia. The goal of this review was to examine the relationship between different types of CK with MDS, as well as its possible role in the deterioration and progression of MDS to leukemia. The content used in this paper has been obtained by a PubMed and Google Scholar search of English language papers (1975-2018) using the terms complex karyotype and myelodysplastic syndromes. A single independent abnormality can be associated with a good prognosis. However, the coexistence of a series of abnormalities can lead to CK, which is associated with the deterioration of MDS and its progression to leukemia. Therefore, CK may be referred to as a prognostic factor in MDS. The detection of independent cytogenetic disorders that altogether can result in CK could be used as a prognostic model for laboratory and clinical use.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"389"},"PeriodicalIF":3.1000,"publicationDate":"2019-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.389","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/oncol.2019.389","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/14 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 8

Abstract

Complex karyotype (CK) is a poor prognosis factor in hematological malignancies. Studies have shown that the presence of CK in myelodysplastic syndrome (MDS) can be associated with MDS progression to acute myeloid leukemia. The goal of this review was to examine the relationship between different types of CK with MDS, as well as its possible role in the deterioration and progression of MDS to leukemia. The content used in this paper has been obtained by a PubMed and Google Scholar search of English language papers (1975-2018) using the terms complex karyotype and myelodysplastic syndromes. A single independent abnormality can be associated with a good prognosis. However, the coexistence of a series of abnormalities can lead to CK, which is associated with the deterioration of MDS and its progression to leukemia. Therefore, CK may be referred to as a prognostic factor in MDS. The detection of independent cytogenetic disorders that altogether can result in CK could be used as a prognostic model for laboratory and clinical use.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

骨髓增生异常综合征的复杂核型:诊断程序和预后易感性。

复杂核型(CK)是血液系统恶性肿瘤预后不良的因素。研究表明，骨髓增生异常综合征(MDS)中CK的存在可能与MDS进展为急性髓系白血病有关。本综述的目的是研究不同类型CK与MDS之间的关系，以及其在MDS恶化和发展为白血病中的可能作用。本文中使用的内容是通过PubMed和Google Scholar检索英语论文(1975-2018)，使用术语复杂核型和骨髓增生异常综合征获得的。单个独立的异常可能与良好的预后相关。然而，一系列异常的共存可导致CK, CK与MDS的恶化和发展为白血病有关。因此，CK可能被认为是MDS的预后因素。检测独立的细胞遗传学疾病，可以共同导致CK，可以作为实验室和临床使用的预后模型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Oncology Reviews ONCOLOGY-

CiteScore

6.30

自引率

0.00%

发文量

审稿时长

9 weeks

期刊介绍： Oncology Reviews is a quarterly peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology. The journal will provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. Oncology Reviews aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice. The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.